Pfizer (NYSE:PFE) Shares Down 0.4%

Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 0.4% during mid-day trading on Tuesday . The company traded as low as $28.40 and last traded at $28.43. Approximately 5,945,216 shares traded hands during trading, a decline of 86% from the average daily volume of 42,291,641 shares. The stock had previously closed at $28.53.

Analysts Set New Price Targets

A number of analysts have weighed in on PFE shares. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. BMO Capital Markets restated an "outperform" rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target for the company. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $35.86.

Pfizer Trading Up 0.1 %

The stock has a market cap of $161.84 billion, a PE ratio of -476.00, a PEG ratio of 1.21 and a beta of 0.63. The business has a 50-day moving average of $27.22 and a 200 day moving average of $27.96. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts' consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 earnings per share. The business's revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.88%. Pfizer's dividend payout ratio is presently -2,800.00%.

Institutional Trading of Pfizer

Institutional investors have recently added to or reduced their stakes in the business. Compass Ion Advisors LLC bought a new position in Pfizer during the 3rd quarter valued at $539,000. Main Street Financial Solutions LLC lifted its position in shares of Pfizer by 5.4% during the third quarter. Main Street Financial Solutions LLC now owns 26,031 shares of the biopharmaceutical company's stock worth $863,000 after purchasing an additional 1,331 shares during the last quarter. KCS Wealth Advisory increased its holdings in Pfizer by 84.2% in the third quarter. KCS Wealth Advisory now owns 22,900 shares of the biopharmaceutical company's stock valued at $760,000 after buying an additional 10,469 shares during the last quarter. SageView Advisory Group LLC raised its stake in Pfizer by 49.0% during the third quarter. SageView Advisory Group LLC now owns 44,213 shares of the biopharmaceutical company's stock valued at $1,467,000 after buying an additional 14,539 shares in the last quarter. Finally, Black Diamond Financial LLC grew its position in shares of Pfizer by 7.4% in the 3rd quarter. Black Diamond Financial LLC now owns 6,319 shares of the biopharmaceutical company's stock worth $210,000 after acquiring an additional 438 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.